Efficacy And Safety Of KSM66 Ashwagandha (Withania somnifera) In Cognitive Function In Healthy Adults: A prospective, Randomized, Double blind, Placebo controlled Study

Shri Kartikeya Pharma0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Adult male or female patients aged greater than 35 years of age
•2.Patients with early dementia or mild cognitive impairment
•3.Have a screening Mini-Mental State Examination (MMSE) score of greater than or equal to 19 (mild or no memory impairment)
•4.Patients with subjective memory complaints
•5.Have the ability to understand the requirements of the study
•6.Participants agree to abide by the study restrictions and return for the required assessments
•7.Participants willing to sign informed consent

•1 Have a screening Mini-Mental State Examination (MMSE) score of less than 19(moderate and severe memory impairment)
•2.Psychiatric with known neuropsychiatric conditions like Schizophrenia, Parkinsonism, Huntingtonâ??s disease, Picks disease etc.
•3.Patients taking psychotropic drugs including alcohol
•4.Patients taking any other drugs or alternative medicines for enhancement of memory
•5.Patients with known persistent endocrine disorders
•6.Patients with uncontrolled hypertension
•7.Patients with uncontrolled diabetes mellitus
•8.H/o of drug dependence or any severe co-morbid medical conditions
•9.Pregnant and lactating women
•10.Subjects with known hypersensitivity to Ashwagandha
•11.History of major surgery within the past 6 months
•12.Participation in other clinical trials during previous 3 months
•13.Any clinical condition, according to the investigator which does not allow safe fulfillment of the study protocol

发起方